Perspective Therapeutics (CATX) 10% Owner Sells Shares

What Happened
Lantheus Alpha Therapy, LLC — a reported 10% owner of Perspective Therapeutics (CATX) — sold shares in two open-market transactions. On 2026-09-03 it disposed of 80,783 shares at a weighted average price of $3.11 for proceeds of about $250,896, and on 2026-09-04 it disposed of 167,149 shares at a weighted average price of $3.15 for proceeds of about $526,051. Total proceeds across both sales were roughly $776,947. These were outright sales (S) by an institutional holder, not purchases.

Key Details

• Transaction dates and reported weighted-average prices:
  • 2026-09-03: 80,783 shares @ $3.11 (total ≈ $250,896). Footnote F1: actual trade prices ranged $3.05–$3.13.
  • 2026-09-04: 167,149 shares @ $3.15 (total ≈ $526,051). Footnote F3: actual trade prices ranged $3.0448–$3.1775.
• Combined shares sold: 247,932; combined proceeds: ≈ $776,947.
• Shares owned after the transactions: not specified in the provided filing.
• Footnote F2: Lantheus Alpha Therapy is a wholly owned indirect subsidiary of Lantheus Holdings, which may be deemed to have indirect beneficial ownership.
• Filing dated 2026-09-08 covering trades on 2026-09-03 and 2026-09-04. The Sep 4 trade was reported within the two-business-day window; the Sep 3 trade appears to have been reported one business day late relative to the two-business-day Form 4 deadline.

Context

• This filing reflects institutional selling by a 10% stockholder rather than an executive officer; such sales can be for many reasons and do not by themselves indicate company performance or insider sentiment.
• No purchases, option exercises, awards, or gifts were reported; these were straight disposals in the open market.
• Footnotes note the weighted-average pricing and the filer’s willingness to provide per-trade price breakdowns to CATX, shareholders, or the SEC upon request.